Literature DB >> 1512911

Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group.

H Buchwald1, J P Matts, L L Fitch, C T Campos, M E Sanmarco, K Amplatz, W R Castaneda-Zuniga, D W Hunter, M B Pearce, J K Bissett.   

Abstract

OBJECTIVE: Assessment of the relationship between changes in sequential coronary arteriograms and subsequent clinical coronary events.
DESIGN: The Program on the Surgical Control of the Hyperlipidemias, a randomized secondary atherosclerosis intervention trial, obtained coronary arteriograms at baseline, 3, 5, and 7 or 10 years of follow-up. Assessments of changes between pairs of coronary arteriograms were made by two-member panels blinded to the patients' assigned treatment and to the temporal sequence of the films. The relationship of changes between the baseline and the 3-year follow-up arteriograms and subsequent clinical coronary events was examined.
SETTING: Three university hospitals and one private primary care facility. PATIENTS: A total of 838 patients, with 417 patients randomized to the control group and 421 to the intervention group. Of all patients, 695 had baseline and 3-year arteriograms. INTERVENTION: The control group received American Heart Association Phase II diet instruction and the intervention group received identical dietary instruction plus a partial ileal bypass operation. MAIN OUTCOME MEASURE: The use of arteriographic changes as a predictor of subsequent clinical coronary events.
RESULTS: Changes between the baseline and the 3-year coronary arteriographic overall disease assessment were significantly associated with subsequent overall and atherosclerotic coronary heart disease mortality (P less than .01). For the combined end point of atherosclerotic coronary heart disease mortality or confirmed nonfatal myocardial infarction, a significant relationship between the overall disease assessment and subsequent clinical events was found in the control group (P less than .0001) and in the surgery group (P = .04). For this combined end point, however, the control and the surgery groups were different with respect to clinical coronary events after 3 years, stratified by the baseline to 3-year overall disease assessment (P less than .001, unadjusted; P = .06, adjusted for 3-year clinical covariates).
CONCLUSIONS: Coronary arteriographic changes can be used in atherosclerosis intervention trials as a limited surrogate end point for certain clinical coronary events. This relationship is statistically compelling for overall mortality and atherosclerotic coronary heart disease mortality. For an individual patient, changes in the severity of coronary atherosclerosis seen on sequential coronary arteriograms can serve as prognostic indicators for subsequent overall or atherosclerotic coronary heart disease mortality.

Entities:  

Mesh:

Year:  1992        PMID: 1512911

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  19 in total

Review 1.  A winter's tale: report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium.

Authors:  Therese Heinonen; David D Waters; Peter Libby; Jean-Claude Tardif
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

Review 2.  Statin treatment and progression of atherosclerotic plaque burden.

Authors:  Diederick E Grobbee; Michiel L Bots
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Gastrointestinal surgery: cardiovascular risk reduction and improved long-term survival in patients with obesity and diabetes.

Authors:  Ted D Adams; Lance E Davidson; Sheldon E Litwin; Steven C Hunt
Journal:  Curr Atheroscler Rep       Date:  2012-12       Impact factor: 5.113

Review 4.  Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? West Of Scotland Coronary Prevention Study.

Authors:  V Maher; J Sinfuego; P Chao; J Parekh
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

5.  Does lipid-lowering therapy promote regression of coronary atheroma?

Authors:  G C Leng; F G Fowkes
Journal:  Br J Gen Pract       Date:  1994-01       Impact factor: 5.386

6.  Coronary calcium scores 6 years after bariatric surgery.

Authors:  Tiffany Priester; Travis G Ault; Lance Davidson; Richard Gress; Ted D Adams; Steven C Hunt; Sheldon E Litwin
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

Review 7.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

8.  Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS).

Authors:  Xue-Qiao Zhao; Richard A Krasuski; Jefferson Baer; Edwin J Whitney; Blazej Neradilek; Alan Chait; Santica Marcovina; John J Albers; B Greg Brown
Journal:  Am J Cardiol       Date:  2009-12-01       Impact factor: 2.778

9.  Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials.

Authors:  H Buchwald; C T Campos; J R Boen; P Nguyen; S E Williams; J Lau; T C Chalmers
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

Review 10.  [Assessment of progression and regression of coronary atherosclerosis by coronary angiography].

Authors:  Raimund Erbel
Journal:  Herz       Date:  2015-09       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.